A Study of Yervoy and Opdivo Combination Therapy in Participants With Unresectable Advanced/Recurrent Malignant Pleural Mesothelioma (MPM)

Bristol-Myers Squibb (BMS) logo

Bristol-Myers Squibb (BMS)

Status

Enrolling

Conditions

Mesothelioma, Malignant

Study type

Observational

Funder types

Industry

Identifiers

NCT05324436
CA209-6AF

Details and patient eligibility

About

The purpose of this study is to observe the safety of the combination therapy with Yervoy and Opdivo in Japanese participants for the treatment of unresectable advanced/recurrent malignant pleural mesothelioma (MPM).

Enrollment

50 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Initiated treatment with Yervoy and Opdivo in combination for the first time in accordance with the Japanese package insert

Exclusion criteria

  • Received combination therapy with Yervoy and Opdivo for indications other than Malignant Pleural Mesothelioma (MPM).
  • Received the Yervoy and Opdivo combination for MPM, but for an indication that is outside of the Japanese package insert.

Trial design

50 participants in 1 patient group

Cohort 1
Description:
Participants with unresectable advanced/recurrent malignant pleural mesothelioma (MPM)

Trial contacts and locations

1

Loading...

Central trial contact

First line of the email MUST contain NCT # and Site #.; BMS Study Connect Contact Center www.BMSStudyConnect.com

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems